Abstract
Background: Despite radical surgical and chemotherapeutic treatment of ovarian cancer, the majority of patients develop recurrent disease. Secondary cytoreductive surgery can result in favourable outcome in selected patients, but information regarding feasibility, safety and perioperative outcome of these often complex procedures is limited.
Methods: Surgical parameters in patients with recurrent epithelial ovarian cancer selected for secondary cytoreduction were analysed and compared to patients undergoing primary cytoreduction.
Results: In total, 222 patients undergoing radical cytoreduction were analysed (48 patients for relapsed disease and 174 patients at primary diagnosis of advanced ovarian cancer). The range of surgical procedures was similar in both groups. In 48% of secondary cytoreductions 'optimal surgical results' (residual tumour
Conclusion: Secondary cytoreduction in relapsed ovarian cancer is safe and feasible and perioperative outcome is not inferior compared to primary cytoreduction. Surgery-associated morbidity should represent a minor aspect in the selection and counselling of patients regarding treatment options for recurrent ovarian cancer. (C) 2010 Elsevier Ltd. All rights reserved.
| Original language | English |
|---|---|
| Pages (from-to) | 583-588 |
| Number of pages | 6 |
| Journal | European Journal of Surgical Oncology |
| Volume | 36 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Jun-2010 |
Keywords
- Ovarian cancer
- Progression
- Relapse
- Cytoreduction
- Morbidity
- SURGICAL CYTOREDUCTION
- SURGERY
- CARCINOMA
- SURVIVAL
- PLATINUM
- IMPROVES
- TRIAL